Skip to main content

Viatris Inc Value Stock - Dividend - Research Selection

Viatris

ISIN: US92556V1061 , WKN: A2QAME

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Barclays Maintains Overweight on Viatris, Raises Price Target to $17

2026-03-24
Barclays analyst Glen Santangelo maintains Viatris (NASDAQ:VTRS) with a Overweight and raises the price target from $15 to $17.

Viatris Stock: Is VTRS Outperforming the Health Care Sector?

2026-03-23
As Viatris has outperformed the broader health care sector over the past year, and analysts remain moderately optimistic about the stock’s prospects.

Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)

2026-03-23
Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Effexor® SR 37.5 mg / 75 mg capsules (venlafaxine hydrochloride), a serotonin-noradrenaline reuptake inhibitor (SNRI), for the treatment of adults with generalized anxiety disorder (GAD). Following the MHLW's decision, Effexor® becomes the first and only approved treatment option in Japan for adults living with GAD, addressing a long-standing unmet med

Viatris Announced That Japan's Ministry Of Health, Labour And Welfare Has Approved Effexor Sr 37.5 Mg / 75 Mg Capsules (Venlafaxine Hydrochloride), A Serotonin-noradrenaline Reuptake Inhibitor, For The Treatment Of Adults With Generalized Anxiety Disorder

2026-03-23

24 Safer Buys From 10 Years Of Dogcatcher Digging

2026-03-22
Explore the Dogcatcher 10-year Dividend Dogs: 90 high-yield “safer” stocks, analyst 2027 gain targets, and free-cash-flow risk flags—read now.

Will Viatris’ 2030 Capital Return And Growth Blueprint Change Viatris' (VTRS) Narrative

2026-03-21
Viatris has already held an Investor Event where its leadership outlined the company’s long-term vision through 2030, including growth priorities, R&D focus, commercial strategy, portfolio management, and a financial framework intended to support revenue and earnings expansion and capital returns. A key insight from the event is Viatris’ emphasis on using anticipated product launches, its pipeline, business development, and cash flow to both return capital to shareholders and reinvest in...

What Investors Should Know About a $24 Million Exit From a Medical Device Stock Down 9% This Past Year

2026-03-20
This medical technology firm delivers integrated blood management solutions to healthcare providers and plasma centers worldwide.

Theravance's Q4 Earnings and Revenues Miss Estimates

2026-03-20
TBPH's posts Q4 earnings miss despite 145% revenue surge; scraps Ampreloxetine, launches restructuring and weighs a potential sale.

Viatris: Is It A Credible Turnaround Or Overly Optimistic 2030 Plan?

2026-03-20
Viatris (VTRS) targets 5–6% revenue and 9–10% EPS CAGR through 2030, backed by launches, pipeline and $11B M&A cash. Click here to read my most recent analysis.

Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030

2026-03-19
Viatris Inc. (Nasdaq: VTRS) will host its Investor Event today, where members of the executive leadership team will outline the Company's strategic vision, key drivers and financial framework expected to deliver sustained revenue and earnings growth through 2030.